US · autoimmune · biotechnology · clinical-stage
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Undisclosed round · Feb 2026 · $144M
Wedbush PacGrow lead, Cantor, Leerink Partners, Piper Sandler
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.